Pharmaceuticals and vector-control programmes have greatly diminished the once-widespread disease, but sustained effort will ...

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the ...

Azafaros B.V. today announced that its lead asset, nizubaglustat, has been granted orphan drug designation from regulatory ...

Patients with presbyopia experienced improvements in near vision after treatment with Brimochol PF in a second phase 3 ...

LONDON, Jan. 7, 2025 /PRNewswire/ -- Norgine today announced that it completed its marketing authorisation application filing ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s ...

Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the ...

Stoke Therapeutics (STOK) announced alignment with global regulatory agencies on the design of the company’s Phase 3 EMPEROR study of ...

Among the health policy novelties of 2025, a new tool developed by the European Medicines Agency (EMA) is set to harmonise ...

Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the <a target=_blank href=https:// ...

Everest Medicines announces the implementation of Nefecon NRDL pricing in China for the treatment for IgA nephropathy: Shanghai, China Saturday, January 4, 2025, 10:00 Hrs [IST] E ...